Hua Er Jie Jian Wen·2025-10-17 04:13Core Viewpoint - President Trump announced that the price of the popular diabetes drug Ozempic could drop to $150 per month, causing significant market reactions and stock declines for Eli Lilly and Novo Nordisk [1]. Group 1: Price Announcement and Market Reaction - Trump stated that the price of Ozempic, currently around $1,000 per month, would "soon significantly decrease" [1]. - Following this announcement, Novo Nordisk's ADR fell by 4.7% and Eli Lilly's stock dropped by up to 5.3% in after-hours trading [1]. Group 2: Ongoing Negotiations - The Centers for Medicare & Medicaid Services (CMS) clarified that price negotiations are still ongoing and no agreement has been reached yet [1][6]. - Ozempic and its sister drug Wegovy are included in the price negotiation list under the Inflation Reduction Act (IRA), facing additional legal pressures [6]. Group 3: Broader Context of Drug Pricing - The Trump administration has previously announced similar agreements with Pfizer and AstraZeneca, indicating a trend of government action against major weight-loss drug manufacturers [5]. - The announcement reflects a strategy by the Trump administration to leverage tariff exemptions in exchange for price reductions, extending from fertility treatment drugs to weight-loss medications [6].